KFF polling finds only about a third of drug users have heard of TrumpRx and most doubt the policies will lower costs

Only about a third of people who take prescription drugs say they have heard of TrumpRx, the federal website that offers discount coupons on certain medicines, according to KFF survey findings. Thirty-five percent of prescription drug users reported being aware of the platform, which KFF describes as launching in early 2026 ^[1][2].

KFF, a health policy research organization, also found deep skepticism about whether federal action is working. Seventy-two percent of adults said there is not enough government regulation of prescription drug prices, a view shared across party lines ^[1]. KFF's own summary puts it slightly differently, saying at least two-thirds of Democrats, independents and Republicans agree there is not enough regulation ^[2]. Fifty-nine percent doubted that current policies would meaningfully lower costs, with Republicans more confident than Democrats and independents, and Medicare beneficiaries split ^[1].

What the numbers show

KFF reported that six in ten adults are worried about being able to afford their prescription drug costs — a new high since the organization began asking the question in 2018 — and that four in ten say they have taken cost-saving measures such as skipping doses or not filling prescriptions ^[2]. A secondary account of the same research put those figures at 66% of Americans taking medications reporting cost concerns and 43% adjusting their medication use because of money, with lower-income households hit hardest ^[1]. The two write-ups do not line up exactly; KFF's own figure of 66% refers to the share of adults currently taking at least one prescription drug, and 31% say they take four or more ^[2].

Affordability tracks closely with how many drugs a person takes and how much they earn. In KFF's data, 28% of adults overall said it is somewhat or very difficult to afford their prescriptions, rising to 37% among those taking four or more medications and 40% among adults in households earning under $40,000, compared with 11% of those earning $90,000 or more ^[2].

On GLP-1 medications specifically, KFF said about one in five adults have ever taken one, and that most users — including those with health insurance — say the drugs are difficult to afford ^[2]. A summary of the same research put the figure at nearly 18% of adults ^[1]. A separate current-use figure was not included in the source material reviewed here. TrumpRx lists many of the major GLP-1 medications, but few people report using it to compare prices or buy, according to that summary ^[1].

Why it matters for patients

A discount website only helps people who know it exists. If roughly two-thirds of prescription drug users have not heard of TrumpRx months after launch, the savings it advertises are not reaching most of the people who might qualify for them ^[1][2]. That gap matters most for GLP-1 users, who face some of the highest monthly out-of-pocket costs of any common medication class and who, by KFF's account, struggle with affordability even when insured ^[2].

The polling also shows that cost pressure is already changing behavior. Skipping doses, stretching supplies and not filling prescriptions are common responses to high prices ^[2], and for weight-loss and diabetes drugs those choices can affect results. Independent discount tools such as GoodRx remain part of how people hunt for lower prices ^[1].

What the sources do not answer is whether TrumpRx coupon prices are actually lower than cash prices, manufacturer direct programs or other discount cards for any specific GLP-1. That comparison is not in this polling, and KFF's data note does not attempt it ^[1][2].

What happens next

KFF's underlying Health Tracking Poll was fielded February 24 to March 2, 2026, and the data note summarizing it was updated March 31, 2026 ^[2]. KFF said it will keep monitoring the public's experiences with GLP-1 medications as use, regulation and new formulations — including oral versions — continue to evolve ^[2].

KFF also found that most adults support policies already on the books, including the 2022 Inflation Reduction Act provisions that let Medicare negotiate prices and limit price increases above inflation ^[2]. On politics, the Democratic Party is more often seen as better able to handle drug affordability, though a sizable share of voters is undecided or skeptical of both parties ^[1].